Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07.
|
Submission of Matters to a Vote of Security Holders. |
The 2017 Annual Meeting of Stockholders of Accelerate
Diagnostics, Inc. (the Company) was held on May 4, 2017. At the
meeting, Tom Brown, Lawrence Mehren, Mark C. Miller, John
Patience, Jack Schuler, Matthew W. Strobeck, Ph.D. and Frank J.M.
ten Brink were elected as directors, each to hold office until
the Companys next Annual Meeting of Stockholders or until his
successor is elected and qualified. A proposal to amend the
Companys 2012 Omnibus Equity Incentive Plan (the Plan) increasing
the number of shares of the Companys common stock reserved and
available for grant thereunder by 2,000,000 shares and to
reapprove the material terms of the Plan for purposes of Section
162(m) of the Internal Revenue Code was also approved at the
meeting. The Audit Committees appointment of Ernst Young LLP as
the Companys independent registered public accounting firm for
the fiscal year ending December 31, 2017 was also ratified at the
meeting.
The voting results of the director elections and other proposals,
which were described in more detail in the definitive proxy
statement relating to the 2017 Annual Meeting of Stockholders
that the Company filed with the Securities and Exchange
Commission on April 10, 2017, are set forth below.
Proposal No. 1 Election of Directors
| Director Nominee | Votes For | Votes Withheld | Broker Non-Votes |
| Tom Brown | 35,026,600 | 2,910,321 | 9,816,461 |
| Lawrence Mehren | 37,788,298 | 148,623 | 9,816,461 |
| Mark C. Miller | 37,431,544 | 505,377 | 9,816,461 |
| John Patience | 36,296,610 | 1,640,311 | 9,816,461 |
| Jack Schuler | 37,788,860 | 148,061 | 9,816,461 |
| Matthew W. Strobeck, Ph.D. | 37,787,223 | 149,698 | 9,816,461 |
| Frank J.M. ten Brink | 37,789,427 | 147,494 | 9,816,461 |
Proposal No. 2 Amendment of Omnibus Equity Incentive Plan
| Description of Proposal | Votes For | Votes Against | Abstentions | Broker Non-Votes |
|
To approve an amendment to the Companys 2012 Omnibus Equity Incentive Plan increasing the number of shares of the Companys common stock reserved for grant thereunder by 2,000,000 and reapprove the material terms of the Plan for purposes of Section 162(m) of the Internal Revenue Code |
36,083,134 | 1,775,831 | 77,956 | 9,816,461 |
Proposal No. 3 Ratification of Auditors
| Description of Proposal | Votes For | Votes Against | Abstentions |
|
To ratify the appointment of Ernst and Young LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2017 |
47,447,776 | 144,836 | 160,770 |
About Accelerate Diagnostics, Inc. (NASDAQ:AXDX)
Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types. The Company is focused on the development of a rapid diagnostic platform, the Accelerate ID/AST System (ID/AST System or Accelerate ID/AST System), intended for the diagnosis of infectious pathogens. The ID/AST System utilizes genotypic technology to identify (ID) infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. The ID/AST System features walk-away automation and consists of a fixed instrument and single-use test kit. Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Recent Trading Information
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) closed its last trading session up +0.25 at 29.50 with 449,260 shares trading hands.
